4.8 Article

The ETS family member GABP alpha modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer

Journal

NUCLEIC ACIDS RESEARCH
Volume 42, Issue 10, Pages 6256-6269

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/nar/gku281

Keywords

-

Funding

  1. National Institute for Health Research Cambridge Biomedical Research Centre
  2. National Cancer Research Prostate Cancer: Mechanisms of Progression and Treatment (ProMPT) [G0500966/75466]
  3. Cambridge Cancer Research Foundation, Cambridge
  4. University of Cambridge, Cambridge
  5. Cancer Research UK, Cambridge
  6. Hutchison Whampoa Limited
  7. Prostate Cancer UK
  8. Cancer Research UK Programme Grant [RG69651/SWAH.001]
  9. Cancer Research UK [22310] Funding Source: researchfish
  10. Medical Research Council [G0900871] Funding Source: researchfish
  11. National Institute for Health Research [CL-2012-14-003] Funding Source: researchfish
  12. MRC [G0900871] Funding Source: UKRI

Ask authors/readers for more resources

In prostate cancer (PC), the androgen receptor (AR) is a key transcription factor at all disease stages, including the advanced stage of castrate-resistant prostate cancer (CRPC). In the present study, we show that GABP alpha, an ETS factor that is up-regulated in PC, is an AR-interacting transcription factor. Expression of GABP alpha enables PC cell lines to acquire some of the molecular and cellular characteristics of CRPC tissues as well as more aggressive growth phenotypes. GABP alpha has a transcriptional role that dissects the overlapping cistromes of the two most common ETS gene fusions in PC: overlapping significantly with ETV1 but not with ERG target genes. GABP alpha bound predominantly to gene promoters, regulated the expression of one-third of AR target genes and modulated sensitivity to AR antagonists in hormone responsive and castrate resistant PC models. This study supports a critical role for GABP alpha in CRPC and reveals potential targets for therapeutic intervention.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available